07.01.2009 Axis-Shield Pre-Close Trading Update

19.12.2008 Antisoma receives FDA approval for oral fludarabine, plans commercialisation deal to bring drug to US patients

16.12.2008 Phase II trial showing improved survival with ASA404 in lung cancer published in British Journal of Cancer

16.12.2008 Axis-Shield and Abbott Sign Agreement to Develop and Manufacture Active-B12 Test for the Architect Analyser

04.12.2008 Japanese Patent Granted for Axis-Shield Anti-CCP Assay for Early Detection of Rheumatoid Arthritis

21.11.2008 Cambridge Consultants module paves the way for the next generation of medical diagnostics

19.11.2008 Oxford Biomedica Announces Six-Month Efficiency Results with Low Dose of Prosavin® in Phase II/II Trial in Parkinson's Disease

14.11.2008 Oxford Biomedica Announces Two Scientific Presentations of PROSAVIN^® in Parkinson’s Disease

05.11.2008 Axis-Shield plc Interim Management Statement

24.10.2008 Oxford Biomedica Reports Data on Association Between Immune Response and Patient Survival From TROVAX^® Trials in Colorectal, Renal and Prostate Cancer

15.10.2008 Axis-Shield AFINION HbA1c Patent Granted in Japan

13.10.2008 Oxford Biomedica Announces Appointment of John Dawson as Chief Executive Officer

07.10.2008 Antisoma and The Institute of Cancer Research to collaborate on novel approach to cancer treatment

07.10.2008 Oxford Biomedica Announces FDA Agreement on Revision for Revision for Ongoing TROVAX^® Phase III Tristy Study

02.10.2008 New technology promises tests for diseases such as cancer in 15 minutes

30.09.2008 Cambridge Consultants recruits Da